BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lacoin L, Hurst M, Hill NR, Gordon J, Geretti AM, Aspinall R, Corless L, Gao-Du Y, Mistry L, Mutimer D. Evolution of the burden of active hepatitis C virus infection in England from September 2015 to September 2016: a repeated cross-sectional analysis. BMJ Open 2019;9:e029066. [PMID: 31383704 DOI: 10.1136/bmjopen-2019-029066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Alotaibi AS, Shamas N, Ansari UU, Sanai FM, Alshahrani A, Fathelrahman AI, Aseeri MA. Impact of Drug Use Policy on the Appropriate Use of Direct Acting Antiviral Agents for Hepatitis C in Saudi Arabia. J Pharm Bioallied Sci 2021;13:317-24. [PMID: 35017888 DOI: 10.4103/jpbs.jpbs_166_21] [Reference Citation Analysis]
2 Hüppe D, Stoehr A, Buggisch P, Mauss S, Klinker H, Teuber G, Hidde D, Lohmann K, Bondin M, Wedemeyer H. The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R). J Viral Hepat 2021. [PMID: 34339561 DOI: 10.1111/jvh.13586] [Reference Citation Analysis]